У нас вы можете посмотреть бесплатно Combining Immunotherapy with Salvage Surgery and IORT for Head & Neck Cancers или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
This webinar reviews published data in head and neck locoregionally persistent or recurrent cancers, where IORT was utilized with salvage surgery. Recent publications are discussed to highlight the effects of immunotherapy on recurrent/metastatic H&N cancer population as well. We review a new Phase I clinical trial that will combine salvage surgery, IORT and Immuno-Oncology at The Ohio State University James Cancer Center for the persistent/recurrent H&N cancer population. Topics discussed in this webinar: The treatment options for salvage H&N cancer patients with IORT The use and effectiveness of immunotherapy in the recurrent/metastatic H&N cancer population The introduction of an exciting new clinical trial that will combine Salvage Surgery, IORT and Immuno-Oncology for these patients Presented by: Dukagjin M. Blakaj, MD, PhD Dukagjin M. Blakaj MD, PhD is the Associate Professor, Associate Director of Clinical Operations and H&N/Skull Base Division Director in the Radiation Oncology department at The Ohio State University Comprehensive Cancer Center. He leads a busy clinical practice in H&N, skin, skull base and CNS malignancies. He is also the H&N-Intraoperative and CNS/Pediatric fellowship director within the radiation oncology department. Dr. Blakaj earned his bachelors and masters in Molecular Biophysics & Biochemistry (MB&B) and Chemistry from Wesleyan University (1999 and 2000); Biochemistry M.S (2004), Biochemistry Ph.D. (2008) and MD (2008) from Albert Einstein College of Medicine. He is on national committees for H&N/skin cancer clinical trials including NCI, ECOG and NRG. His research interests are clinical and translational in nature with his goal being to tailor cancer treatments to patients based on their molecular profiles of treatment resistance and conduct research that will ultimately lead to novel clinical trials.